StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) company profile

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.11+0.12 (+0.75%)

Close on Nov 17, 2026Market cap $2.98BP/E –Yield –

About Legend Biotech

Pharmaceutical Preparations, SIC 2834

Legend Biotech Corporation is a global biopharmaceutical enterprise that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other medical indications. Its lead commercial product is CARVYKTI (ciltacabtagene autoleucel), an autologous CAR-T cell therapy targeting B-cell maturation antigen, developed in partnership with Janssen for treating patients with relapsed or refractory multiple myeloma. In addition to cilta-cel, the company pursues an exploratory pipeline of autologous and allogeneic CAR-T and CAR-NK product candidates for solid tumors, hematologic malignancies, and autoimmune disorders. Its primary treatments serve adult cancer patients who have experienced disease progression following multiple prior lines of therapy.

The company operates internationally with approximately 2,900 employees located across the United States, China, and Europe. It maintains principal manufacturing and research and development facilities situated in the United States, Belgium, and China, enabling both clinical supply and commercial delivery across global markets. Legend Biotech Corporation maintains its principal executive offices in Somerset, New Jersey.

Summary of the business section of Legend Biotech's latest annual report, written by StockData.

Company profile

Company

Legal name
Legend Biotech Corp
Founded
2015
Headquarters
Somerset, NJ
Address
2101 Cottontail Lane 08873
Phone
(732) 850-5598
Employees
2,900, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Iselin, New Jersey

Stock & identifiers

Ticker
LEGN
Exchange
Nasdaq
IPO date
Jun 8, 2020
Shares outstanding
370M, Dec 31, 2025
Filer category
Large accelerated filer
SEC CIK
1801198
CUSIP
52490G102
ISIN
US52490G1022
FIGI
BBG00TTGH5W4
Share class FIGI
BBG00TTGH6N2
LEI
254900EIUFZTW136H859
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ying HuangChief Executive Officer, Director238,490
Carlos E. SantosChief Financial Officer19,676
Ingrid ZhangChief Executive Officer1,131,860
Alan BashInterim CEO35,142
Peter SaloveyDirector75,096
Corazon (Corsee) D. SandersDirector52,731
Tomas J. HeymanDirector53,720
Li MaoDirector65,316
Darren Xiaohui JiDirector92,103
Patrick John CaseyDirector69,590
Fangliang ZhangDirector–
Ye WangDirector16
Robin MengDirector–
Gareth KungDirector31,486

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 8, 2020
Offer price
$23.00
Securities offered
18,425,000
Gross proceeds
$423.78M
Exchange
Nasdaq
First trading day
Jun 5, 2020
First-day close
$37.00+60.9%
Lock-up ends (est.)
Dec 2, 2020

“The initial public offering price per ADS is $23.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 2,900 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?